Radius Health's ($RDUS) shares slipped on Tuesday after the company said it was postponing a planned FDA filing for its osteoporosis drug. But CEO Robert Ward ...
If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of Sections 240.13d-1(e), ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results